Author: Customer Service

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals significant survival benefit in right-sided tumors. AUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by the French National Cancer Institute (INCa) and coordinated by investigators at the Centre Georges-François Leclerc (CGFL) in Dijon, France—evaluated the addition of XBiotech’s anti-IL-1α monoclonal antibody, XB2001 (Natrunix™, vilamakitug), to standard-of-care trifluridine/tipiracil (TAS-102) with or without bevacizumab...

WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) — Live Oak Bank has been named the top SBA 7(a) lender by dollar amount, according to rankings from the U.S. Small Business Administration. The SBA posted the rankings on its website. They cover the agency’s 2026 fiscal year, which ended Sept. 30, 2026. “Small businesses are the backbone of the American economy, and the SBA 7(a) program is one of the most effective tools we have to help them start, grow and create jobs in their communities,” said James S. (Chip) Mahan III, chairman and CEO of Live Oak Bancshares. “Being recognized as the nation’s most active 7(a) lender is a tremendous honor, and it reflects our responsibility to keep capital flowing to the entrepreneurs who power local economies across the country.” Live Oak approved 2,411 loans...

DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) — CSW Industrials, Inc. (NYSE: CSW) announced that it will release its earnings results for the fiscal second quarter ended September 30, 2026, on Thursday, October 29, 2026, before the market opens. The Company will host a conference call the same day at 10:00 am Eastern Time to discuss the results. Participants may access the call at 1-877-407-0784, international callers may use 1-201-689-8560, and request to join the CSW Industrials earnings call. A live webcast will also be available at https://ir.csw.com. A telephone replay will be made available shortly following the conclusion of the call and until November 12, 2026. Participants may access the replay at 1-844-512-2921, international callers may use 1-412-317-6671 and enter access code 13763154. An archived replay of the call will also...

WEST ORANGE, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) — Bel Fuse Inc. (Nasdaq: BELFA and BELFB), a global designer, manufacturer, and provider of critical electronic components, systems and solutions for customers in aerospace, defense, industrial, and data-driven markets, today announced plans to release preliminary financial results for the third quarter after market close on Wednesday, October 28, 2026. An earnings conference call has been scheduled as follows:When: Thursday, October 29, 2026 at 8:30 a.m. ET   Dial in: 877.407.0784, or international: 201.689.8560   Online: https://ir.belfuse.com/events-and-presentations   How: Live over the internet – Simply log on to the web at the address above   Replay: 844.512.2921, or international: 412.317.6671     Conference ID: 13762729A replay will...

Collaboration focuses on the potential of Power Purchase Agreements, energy-efficient mechanical systems, and innovative financing solutions for commercial buildings BEVERLY HILLS, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) — Green Rain Energy Holdings Inc. (OTC: GREH), a clean-energy company focused on renewable power solutions through its subsidiary, Green Rain Development, is highlighting the potential of commercial energy infrastructure opportunities through its channel partnership with MES Mechanical Energy Solutions.The partnership provides a channel through which Green Rain Energy Holdings can explore opportunities involving commercial building energy systems, energy-efficiency improvements, and financing structures designed to help businesses evaluate infrastructure modernization. As commercial property owners face increasing...

In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing Practices” (GMP). NRx has additionally received two year stability data consistent with projected room-temperature stability to three years and beyond with no need for toxic preservatives. Commercially-releasable drug supply is now on hand pending ANDA approval for this drug-shortage product.WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announces completion of three Process Validation...

ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Thursday, October 29, 2026, at 4:30 p.m. ET to discuss these results. Following management’s prepared remarks and discussion of business results, the call will be open for questions. A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at https://ir.supernus.com/events-and-presentations. Participants...

RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) — Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be released at 7:00 a.m. U.S. EDT and will be available on the Company’s website at www.indivior.com. About Indivior As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals...

BOCA RATON, Fla., Oct. 19, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (NASDAQ: NEWT) (“NewtekOne” or the “Company”) announced that its bank subsidiary, Newtek Bank, N.A. (“Newtek Bank”), has launched Zelle® for eligible small business banking clients, enabling a fast, reliable way to send and receive payments through Newtek Bank’s digital banking experience. Offering Zelle to eligible small business banking clients reinforces NewtekOne’s commitment to delivering integrated banking, payments and business solutions that help independent business owners grow revenue, reduce expenses, and reduce risk. “We are pleased to offer Zelle to our eligible small business banking clients,” said Barry Sloane, Chief Executive Officer of NewtekOne. “Independent business owners increasingly expect the ability to reliably send and receive money, whether...

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced it will host a virtual Research Day on Wednesday, November 4, 2026 at 9:30 a.m. ET. During the event, Wave will share new data highlighting its differentiated RNA medicines platform, including its best-in-class chemistry, hepatic and extra-hepatic capabilities, and RNAi, RNA editing, and bifunctional modalities. The event will also feature perspectives on PNPLA3 I148M liver disease and the opportunity for an RNA editing correction approach from Arun J. Sanyal, MD, FAASLD, a leading hepatologist. Dr. Sanyal is a Z Reno Vlahcevic Professor of Medicine and Director of the Stravitz-Sanyal Institute for Liver Disease...